Choose the most potent and most efficacious LDLcholesterol lowering HMG-CoA reductase inhibitor: A. Lovastatin B. Simvastatin C. Pravastatin D. Atorvastatin

Choose the most potent and most efficacious LDLcholesterol lowering HMG-CoA reductase inhibitor:
A. Lovastatin
B. Simvastatin
C. Pravastatin
D. Atorvastatin
by

1 Answer

Answer :

D. Atorvastatin
by

Related questions

Features of atorvastatin include the following: A. Dose to dose most potent HMG-CoA reductase inhibitor B. Higher ceiling of LDL-cholesterol lowering action than lovastatin C. Antioxidant property D. All of the above

Description : Features of atorvastatin include the following: A. Dose to dose most potent HMG-CoA reductase inhibitor B. Higher ceiling of LDL-cholesterol lowering action than lovastatin C. Antioxidant property D. All of the above

Last Answer : D. All of the above

The following is true of simvastatin except: A. It is more potent than lovastatin B. At the highest recommended dose, it causes greater LDL-cholesterol lowering than lovastatin C. It does not undergo first pass metabolism in liver D. It can raise HDL-cholesterol level when the same is low at base line

Description : The following is true of simvastatin except: A. It is more potent than lovastatin B. At the highest recommended dose, it causes greater LDL-cholesterol lowering than lovastatin C. It does not undergo ... metabolism in liver D. It can raise HDL-cholesterol level when the same is low at base line

Last Answer : C. It does not undergo first pass metabolism in liver

Lovastatin is a (A) Competitive inhibitor of acetyl CoA carboxylase (B) Competitive inhibitor of HMG CoA synthetase (C) Non-competitive inhibitor of HMG CoA reductase (D) Competitive inhibitor of HMG CoA reductase

Description : Lovastatin is a (A) Competitive inhibitor of acetyl CoA carboxylase (B) Competitive inhibitor of HMG CoA synthetase (C) Non-competitive inhibitor of HMG CoA reductase (D) Competitive inhibitor of HMG CoA reductase

Last Answer : Answer : D

Select the most appropriate hypolipidemic drug for a patient with raised LDL-cholesterol level but normal triglyceride level: A. A HMG-CoA reductase inhibitor B. A fibric acid derivative C. Gugulipid D. Nicotinic acid

Description : Select the most appropriate hypolipidemic drug for a patient with raised LDL-cholesterol level but normal triglyceride level: A. A HMG-CoA reductase inhibitor B. A fibric acid derivative C. Gugulipid D. Nicotinic acid

Last Answer : A. A HMG-CoA reductase inhibitor

A metabolite obtained from Aspergillus terreus that can bind very tightly to HMG CoA reductase enzyme is (A) Fluvastatin (B) Cerivastatin (C) Lovastatin (D) Somatostatin

Description : A metabolite obtained from Aspergillus terreus that can bind very tightly to HMG CoA reductase enzyme is (A) Fluvastatin (B) Cerivastatin (C) Lovastatin (D) Somatostatin

Last Answer : (C) Lovastatin

The activity of HMG-CoA reductase is inhibited by (A) A fungal inhibitor mevastatin (B) Probucol (C) Nicotinic acid (D) Clofibrate

Description : The activity of HMG-CoA reductase is inhibited by (A) A fungal inhibitor mevastatin (B) Probucol (C) Nicotinic acid (D) Clofibrate

Last Answer : Answer : A

Select the first line hypolipidemic drug/drugs for treating hypertriglyceridemia in a subject with normal cholesterol level: A. Fibrates B. HMG-CoA reductase inhibitors C. Nicotinic acid D. Both 'A' and 'C' are correc

Description : Select the first line hypolipidemic drug/drugs for treating hypertriglyceridemia in a subject with normal cholesterol level: A. Fibrates B. HMG-CoA reductase inhibitors C. Nicotinic acid D. Both 'A' and 'C' are correc

Last Answer : D. Both 'A' and 'C' are correct

Select the hypolipidemic drug that enhances lipoprotein synthesis, fatty acid oxidation and LDLreceptor expression in liver through paroxisome proliferator-activated receptor α: A. Lovastatin B. Atorvastatin C. Bezafibrate D. Nicotinic acid

Description : Select the hypolipidemic drug that enhances lipoprotein synthesis, fatty acid oxidation and LDLreceptor expression in liver through paroxisome proliferator-activated receptor α: A. Lovastatin B. Atorvastatin C. Bezafibrate D. Nicotinic acid

Last Answer : C. Bezafibrate

Choose the correct statement about lovastatin: A. It markedly lowers plasma triglyceride with little effect on cholesterol level B. It is used as an adjuvant to gemfibrozil for type III hyperlipoproteinemia C. It is not effective in diabetes associated hypercholesterolemia D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

Description : Choose the correct statement about lovastatin: A. It markedly lowers plasma triglyceride with little effect on cholesterol level B. It is used as an adjuvant to gemfibrozil for type III ... hypercholesterolemia D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

Last Answer : D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis

HMG-CoA reductase activity is increased by administration of the hormone: (A) Insulin (B) Glucagon (C) Epinephrine (D) Glucocorticoids

Description : HMG-CoA reductase activity is increased by administration of the hormone: (A) Insulin (B) Glucagon (C) Epinephrine (D) Glucocorticoids

Last Answer : Answer : A

Cholesterol by a feed back mechanism inhibits the activity of (A) HMG-CoA synthetase (B) HMG-CoA reductase (C) Thilase (D) Mevalonate kinase

Description : Cholesterol by a feed back mechanism inhibits the activity of (A) HMG-CoA synthetase (B) HMG-CoA reductase (C) Thilase (D) Mevalonate kinase

Last Answer : Answer : B

In the biosynthesis of cholesterol, the rate limiting enzyme is (A) Mevalonate kinase (B) HMG-CoA synthetase (C) HMG-CoA reductase (D) Cis-prenyl transferase

Description : In the biosynthesis of cholesterol, the rate limiting enzyme is (A) Mevalonate kinase (B) HMG-CoA synthetase (C) HMG-CoA reductase (D) Cis-prenyl transferase

Last Answer : Answer : C

For reduction enzyme HMG-CoA reductase requires cofactor: (A) NADPH (B) NADP (C) NAD (D) FAD

Description : For reduction enzyme HMG-CoA reductase requires cofactor: (A) NADPH (B) NADP (C) NAD (D) FAD

Last Answer : Answer : A

HMG-CoA is converted to mevalonate by reduction catalysed by (A) HMG-CoA synthetase (B) HMG-CoA reductase (C) Mevalonate kinase (D) Thiolase

Description : HMG-CoA is converted to mevalonate by reduction catalysed by (A) HMG-CoA synthetase (B) HMG-CoA reductase (C) Mevalonate kinase (D) Thiolase

Last Answer : Answer : B

The rage limiting step cholesterol biosynthesis is (A) Squalene synthetase (B) Mevalonate kinase (C) HMG CoA synthetase (D) HMG CoA reductase

Description : The rage limiting step cholesterol biosynthesis is (A) Squalene synthetase (B) Mevalonate kinase (C) HMG CoA synthetase (D) HMG CoA reductase

Last Answer : Answer : D

An enzyme required for the synthesis of ketone bodies as well as cholesterol is (A) Acetyl CoA carboxylase (B) HMG CoA synthetase (C) HMG CoA reductase (D) HMG CoA lyase

Description : An enzyme required for the synthesis of ketone bodies as well as cholesterol is (A) Acetyl CoA carboxylase (B) HMG CoA synthetase (C) HMG CoA reductase (D) HMG CoA lyase

Last Answer : Answer : B

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

Choose the correct statement about nefopam: A. It is a nonopioid analgesic which does not inhibit prostaglandin synthesis B. It is an orally active opioid analgesic C. It is an analgesic with potent antiinflammatory activity D. It is a preferential COX-2 inhibitor

Description : Choose the correct statement about nefopam: A. It is a nonopioid analgesic which does not inhibit prostaglandin synthesis B. It is an orally active opioid analgesic C. It is an analgesic with potent antiinflammatory activity D. It is a preferential COX-2 inhibitor

Last Answer : A. It is a nonopioid analgesic which does not inhibit prostaglandin synthesis

If the patient has a history of gout, which of the following drugs is most likely to exacerbate this condition? (a) Colestipol (b) Gemfibrozil (c) Lovastatin (d) Niacin (e) Simvastatin

Description : If the patient has a history of gout, which of the following drugs is most likely to exacerbate this condition? (a) Colestipol (b) Gemfibrozil (c) Lovastatin (d) Niacin (e) Simvastatin

Last Answer : Ans: D

Which of the following is an efficacious antiinflammatory drug but a relatively weak inhibitor of cyclooxygenase: A. Nimesulide B. Paracetamol C. Ketoprofen D. Indomethacin

Description : Which of the following is an efficacious antiinflammatory drug but a relatively weak inhibitor of cyclooxygenase: A. Nimesulide B. Paracetamol C. Ketoprofen D. Indomethacin

Last Answer : A. Nimesulide

The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Description : The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Last Answer : A. α-methyl-p-tyrosine

Which of the following is a steroid 5α-reductase inhibitor that has been found useful in benign prostatic hypertrophy and male pattern baldness: A. Flutamide B. Finasteride C. Prazosin D. Minoxidil

Description : Which of the following is a steroid 5α-reductase inhibitor that has been found useful in benign prostatic hypertrophy and male pattern baldness: A. Flutamide B. Finasteride C. Prazosin D. Minoxidil

Last Answer : B. Finasteride

Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Description : Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Last Answer : D. It is unlikely to produce anti-androgenic side effects

Sulbactam differs from clavulanic acid in that: A. It is not a progressive inhibitor of β-lactamase B. It does not inhibit β-lactamase produced by gram negative bacilli C. It is quantitatively more potent D. It per se inhibits N.gonorrhoeae

Description : Sulbactam differs from clavulanic acid in that: A. It is not a progressive inhibitor of β-lactamase B. It does not inhibit β-lactamase produced by gram negative bacilli C. It is quantitatively more potent D. It per se inhibits N.gonorrhoeae

Last Answer : D. It per se inhibits N.gonorrhoeae

n a 50-year-old male without any other coronary artery disease risk factor, hypocholesterolemic drugs are considered necessary when the serum LDLcholesterol level is higher than: A. 130 mg/dl B. 160 mg/dl C. 190 mg/dl D. 240 mg/d

Description : n a 50-year-old male without any other coronary artery disease risk factor, hypocholesterolemic drugs are considered necessary when the serum LDLcholesterol level is higher than: A. 130 mg/dl B. 160 mg/dl C. 190 mg/dl D. 240 mg/d

Last Answer : C. 190 mg/dl

Which of the following hypolipidemic drugs is most effective in raising HDL-cholesterol level and lowers serum triglycerides: A. Nicotinic acid B. Fenofibrate C. Cholestyramine D. Pravastatin

Description : Which of the following hypolipidemic drugs is most effective in raising HDL-cholesterol level and lowers serum triglycerides: A. Nicotinic acid B. Fenofibrate C. Cholestyramine D. Pravastatin

Last Answer : A. Nicotinic acid

Choose the drug that selectively blocks AT1 subtype of angiotensin receptors: A. Ramipril B. Lovastatin C. Candesartan D. Sumatriptan

Description : Choose the drug that selectively blocks AT1 subtype of angiotensin receptors: A. Ramipril B. Lovastatin C. Candesartan D. Sumatriptan

Last Answer : C. Candesartan

Choose the correct statement about H2 receptor blockers: A. They are the most efficacious drugs in inhibiting gastric acid secretion B. They cause fastest healing of duodenal ulcers C. They prevent stress ulcers in the stomach D. They afford most prompt relief of ulcer pain

Description : Choose the correct statement about H2 receptor blockers: A. They are the most efficacious drugs in inhibiting gastric acid secretion B. They cause fastest healing of duodenal ulcers C. They prevent stress ulcers in the stomach D. They afford most prompt relief of ulcer pain

Last Answer : C. They prevent stress ulcers in the stomach

The primary biochemical lesion in homozygote with familial hypercholesterolemia (type IIa) is (A) Loss of feed back inhibition of HMG reductase (B) Loss of apolipoprotein B (C) Increased production of LDL from VLDL (D) Functional deficiency of plasma membrane receptors for LDL

Description : The primary biochemical lesion in homozygote with familial hypercholesterolemia (type IIa) is (A) Loss of feed back inhibition of HMG reductase (B) Loss of apolipoprotein B (C) Increased production of LDL from VLDL (D) Functional deficiency of plasma membrane receptors for LDL

Last Answer : Answer : D

Select the drug which reduces cholesterol synthesis in liver, increases expression of LDL receptors on hepatocytes and has been found to reduce mortality due to coronary artery disease: A. Simvastatin B. Nicotinic acid C. Gemfibrozil D. Colestipol (p. 577, 578) 43.1 4 3 . 1 D 43.2 4 3 . 2 C 43.3 4 3 . 3 A 43.4 4 3 . 4 A Ai

Description : Select the drug which reduces cholesterol synthesis in liver, increases expression of LDL receptors on hepatocytes and has been found to reduce mortality due to coronary artery disease: A. Simvastatin B. Nicotinic acid C. Gemfibrozil D. Colestipol (

Last Answer : A. Simvastatin

Which of the following is a nonselective but very potent and efficacious bonchodilator that is not active by the oral route? (a) Aminophyline (b) Cromolyn (c) Epinephrine (d) Ipratropium (e) Metaproterenol

Description : Which of the following is a nonselective but very potent and efficacious bonchodilator that is not active by the oral route? (a) Aminophyline (b) Cromolyn (c) Epinephrine (d) Ipratropium (e) Metaproterenol

Last Answer : Ans: C

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Description : Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Last Answer : D. A more potent drug can produce the same response at lower doses

If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Description : If the dose-response curves of a drug for producing different actions are widely separated on the dose axis, the drug is: A. Highly potent B. Highly efficacious C. Highly toxic D. Highly selective

Last Answer : D. Highly selective

Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Description : Which of the following is always true: A. A more potent drug is more efficacious B. A more potent drug is safer C. A more potent drug is clinically superior D. A more potent drug can produce the same response at lower doses

Last Answer : D. A more potent drug can produce the same response at lower doses

The most efficacious inhibitor of catecholamine synthesis in the body is (a) a - methyl – p - tyrosine (b) a - methyldopa (c) a - methyl - norepinephrine (d) Pyrogallol

Description : The most efficacious inhibitor of catecholamine synthesis in the body is (a) a - methyl – p - tyrosine (b) a - methyldopa (c) a - methyl - norepinephrine (d) Pyrogallol

Last Answer : Ans: A

The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Description : The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Last Answer : A. α-methyl-p-tyrosine

Which hypolipidemic drug has been used to control and prevent pancreatitis in familial hypertriglyceridemia: A. Lovastatin B. Nicotinic acid C. Cholestyramine D. Clofibrate

Description : Which hypolipidemic drug has been used to control and prevent pancreatitis in familial hypertriglyceridemia: A. Lovastatin B. Nicotinic acid C. Cholestyramine D. Clofibrate

Last Answer : B. Nicotinic acid

A patient with coronary artery disease has raised serum triglyceride level (500 mg/dl) but normal total cholesterol level (150 mg/dl). Which hypolipidemic drug should be prescribed: A. Probucol B. Gemfibrozil C. Cholestyramine D. Lovastatin

Description : A patient with coronary artery disease has raised serum triglyceride level (500 mg/dl) but normal total cholesterol level (150 mg/dl). Which hypolipidemic drug should be prescribed: A. Probucol B. Gemfibrozil C. Cholestyramine D. Lovastatin

Last Answer : B. Gemfibrozil

Select the hypocholesterolemic drug which interferes with intestinal absorption of bile salts and cholesterol, and secondarily increases cholesterol turnover in the liver: A. Gemfibrozil B. Cholestyramine C. Lovastatin D. Bezafibrate

Description : Select the hypocholesterolemic drug which interferes with intestinal absorption of bile salts and cholesterol, and secondarily increases cholesterol turnover in the liver: A. Gemfibrozil B. Cholestyramine C. Lovastatin D. Bezafibrate

Last Answer : B. Cholestyramine

Choose the correct statement about amiloride: A. It antagonises the action of aldosterone B. It can be used to treat lithium induced diabetes insipidus C. It increases calcium loss in urine D. It is dose to dose less potent than triamterene

Description : Choose the correct statement about amiloride: A. It antagonises the action of aldosterone B. It can be used to treat lithium induced diabetes insipidus C. It increases calcium loss in urine D. It is dose to dose less potent than triamterene

Last Answer : B. It can be used to treat lithium induced diabetes insipidus

Choose the correct statement about codeine: A. It has a lower oral: parenteral activity ratio than morphine B. It is devoid of abuse liability C. It is a weaker analgesic than morphine D. It is a more potent antitussive than morphine

Description : Choose the correct statement about codeine: A. It has a lower oral: parenteral activity ratio than morphine B. It is devoid of abuse liability C. It is a weaker analgesic than morphine D. It is a more potent antitussive than morphine

Last Answer : C. It is a weaker analgesic than morphine

Insulin decreases the activity of (A) cAMP dependent protein kinase (B) HMG CoA-reductas (C) Phosphodiesterase (D) Acetyl CoA-carboxylase

Description : Insulin decreases the activity of (A) cAMP dependent protein kinase (B) HMG CoA-reductas (C) Phosphodiesterase (D) Acetyl CoA-carboxylase

Last Answer : Answer : A

In the biosynthesis of cholesterol, the step which controls the rate and locus of metabolic regulation is (A) Geranyl pyrophosphate farnesyl pyrophosphate (B) Squalene → lanosterol (C) HMG CoA → mevalonate (D) Lanosterol → 1, 4-desmethyl lanosterol

Description : In the biosynthesis of cholesterol, the step which controls the rate and locus of metabolic regulation is (A) Geranyl pyrophosphate farnesyl pyrophosphate (B) Squalene → lanosterol (C) HMG CoA → mevalonate (D) Lanosterol → 1, 4-desmethyl lanosterol

Last Answer : Answer : C

NAD is required as a coenzyme for (A) Malate dehydrogenase (B) Succinate dehydrogenase (C) Glucose-6-phosphate dehydrogenase (D) HMG CoA reductae

Description : NAD is required as a coenzyme for (A) Malate dehydrogenase (B) Succinate dehydrogenase (C) Glucose-6-phosphate dehydrogenase (D) HMG CoA reductae

Last Answer : Answer : A

The ‘Committed step’ in the biosynthesis of cholesterol from acetyl CoA is (A) Formation of acetoacetyl CoA from acetyl CoA (B) Formation of mevalonate from HMG CoA (C) Formation of HMG CoA from acetyl CoA and acetoacetyl CoA (D) Formation of squalene by squalene synthetase

Description : The ‘Committed step’ in the biosynthesis of cholesterol from acetyl CoA is (A) Formation of acetoacetyl CoA from acetyl CoA (B) Formation of mevalonate from HMG CoA (C) Formation of HMG CoA from acetyl CoA and acetoacetyl CoA (D) Formation of squalene by squalene synthetase

Last Answer : Answer : B

HMG CoA is formed in the metabolism of (A) Cholesterol, ketones and leucine (B) Cholesterol, fatty acid and Leucine (C) Lysine, Lecuine and Isoleucine (D) Ketones, Leucine and Lysine

Description : HMG CoA is formed in the metabolism of (A) Cholesterol, ketones and leucine (B) Cholesterol, fatty acid and Leucine (C) Lysine, Lecuine and Isoleucine (D) Ketones, Leucine and Lysine

Last Answer : Answer : A

A hydrocarbon formed in cholesterol synthesis is (A) Mevalonate (B) HMG CoA (C) Squalene (D) Zymosterol

Description : A hydrocarbon formed in cholesterol synthesis is (A) Mevalonate (B) HMG CoA (C) Squalene (D) Zymosterol

Last Answer : Answer : C

What is HMG CoA synthase?

Description : What is HMG CoA synthase?

Last Answer : It is the rate-limiting-enzyme in ketogenesis pathway.